Rockwell Medical, Inc. (RMTI) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.92. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is RMTI = $3 (+227.1% upside).
Valuation: RMTI trades at a trailing Price-to-Earnings (P/E) of -6.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.08.
Financials: revenue is $69M, +1.5%/yr average growth. Net income is $5M (loss), growing at -284.6%/yr. Net profit margin is -7.7% (negative). Gross margin is 16.9% (+11.3 pp trend).
Balance sheet: total debt is $12M against $37M equity (Debt-to-Equity (D/E) ratio 0.34, conservative). Current ratio is 3.98 (strong liquidity). Debt-to-assets is 21.8%. Total assets: $57M.
Analyst outlook: 10 / 16 analysts rate RMTI as buy (63%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 30/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 22/100 (Fail), Future 73/100 (Pass), Income 10/100 (Fail).
